Investor Presentaiton
Investor Presentation
First six months of 2018
Slide 78
In the completed PIONEER trials between 52-80% of
patients on oral semaglutide achieved an HbA1c level <7%
In completed PIONEER trials 52-80% of patients
achieved an HbA1c level <7.0% (ADA guidance)¹
Proportion of patients (%)
In completed PIONEER trials 28-49% of patients
achieved a weight loss of ≥ 5%¹
Proportion of patients (%)
100%
100%
80%*
80%
*
72%
80%
69%*
*
60%
40%
20%
0%
lill
PIONEER 1 PIONEER 2 PIONEER 3 PIONEER 4 PIONEER 7
63%
52%
60%
*
*
49%
47%
44%
*
35%
40%
28%*
20%
0%
PIONEER 1 PIONEER 2 PIONEER 3 PIONEER 4 PIONEER 7
1 Hypothetical estimand, observed data
* Statistically significant vs comparator (PIONEER 1 vs placebo; PIONEER 2 vs empagliflozin 25 mg;
PIONEER 3 vs sitagliptin 100 mg; PIONEER 4 vs VictozaⓇ 1.8 mg; PIONEER 7 vs sitagliptin 100 mg)
Note: results shown are: PIONEER 1 for 26 weeks with 14 mg oral semaglutide, PIONEER 2 and 4 for 52
weeks with 14 mg oral semaglutide; PIONEER 3 for 78 weeks with 14 mg oral semaglutide; PIONEER 7
for 52 weeks with a mixed dose
Source: Novo Nordisk data on fileView entire presentation